Amaroq Therapeutics

Amaroq Therapeutics is a dynamic biotechnology company dedicated to pioneering a novel class of therapeutics targeting lncRNA in cancer. With a focus on long non-coding RNAs, often referred to as the "dark matter" of the human genome, Amaroq Therapeutics is at the forefront of innovative therapeutic approaches for multiple indications.

Based in Auckland, New Zealand, with a primary address at 15 Customs St W, Level 22, PwC Tower, Auckland, 1010, NZ, Amaroq Therapeutics is committed to advancing cancer treatment through targeting lncRNAs. The company's research team has identified lncRNA molecules highly expressed in cancer cells, and their removal has demonstrated a slowdown in cancer cell growth. This breakthrough positions Amaroq Therapeutics as a leader in the development of cutting-edge cancer therapeutics.

Supported by significant funding, Amaroq Therapeutics is poised for continued growth and success in the biotechnology sector. We invite the manager of Amaroq Therapeutics to create a customized and exclusive company showcase and product listing on our platform to further enhance its visibility and commercial opportunities.